Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fukuoka
Clinical trial register · Japan

Clinical Trials in Fukuoka, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2516 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2516
Studies in scope
all four open statuses
1285
Recruiting now
open to new participants
352
Lead sponsors
across recruiting studies
Top sites
Fukuoka 557 Nagoya 513 Sapporo 400 Tokyo 375 Osaka 354
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca87 GlaxoSmithKline33 Eli Lilly and Company33 Janssen Research & Development, LLC25 AbbVie23 Hoffmann-La Roche22 Novartis Pharmaceuticals20 Merck Sharp & Dohme LLC18 Daiichi Sankyo17 Pfizer17 Amgen16 Bristol-Myers Squibb14 Ono Pharmaceutical Co., Ltd.13 Takeda10 Sanofi10 Novo Nordisk A/S9 Genmab8 Incyte Corporation7 Astellas Pharma Global Development, Inc.6 Celgene5 Otsuka Medical Devices Co., Ltd. Japan4 National Cancer Center, Japan4 Seagen, a wholly owned subsidiary of Pfizer4 Kyushu University4 Ferring Pharmaceuticals3 Show all 129
Site location
Fukuoka557 Nagoya513 Sapporo400 Tokyo375 Osaka354 Chiba328 Kashiwa317 Yokohama272 Kobe239 Kyoto231 Hiroshima224 Sendai207 Chūōku202 Matsuyama172 Bunkyō City171 Kanazawa149 Kumamoto147 Okayama133 Kashiwa-shi132 Niigata120 Fukushima114 Kagoshima107 Kanagawa105 Aichi104 Gifu103 Show all 938
All 938 locations
Target enrolment
to

Trials with a site in Fukuoka

557 of 2516 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Sapporo, Yokohama, Suita, Bunkyo-ku, Fukuoka, Maebashi, Okayama
2027-02-03
Not yet open
National Cancer Center, Japan
Phase 2
27
Fukuoka, Hiroshima, Nagoya, Takatsuki, Tokyo
2027-01-01
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Nagoya, Seto-shi, Kamogawa-Shi, Eiheiji-cho, Yoshida-gun, Chikushino-shi, Fukuoka, Iizuka-shi, Kurume-Shi
2026-12-16
Not yet open
Tezepelumab CRSwNP Real World Study (CREW Study)
NCT07790198Chronic Rhinosinusitis With Nasal Polyps
DrugTezepelumab
AstraZeneca
Observational
100
Chiba, Fukui, Fukuoka, Gunma, Hiroshima, Hokkaido, Hyōgo, Ishikawa
2026-11-30
Recruiting
argenx
Phase 2
120
Fukuoka, Sapporo
2026-11-05
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Chiba-shi, Chiba, Fuchu-shi,Tokyo, Fukuoka, Himeji-shi, Hyogo, Hyōgo, Kanagawa, Kumamoto-shi, Kumamoto, Kyoto-shi, Kyoto
2026-10-26
Recruiting
Novartis Pharmaceuticals
Observational
80
Toyoake, Fukuoka, Kyoto, Kodaira
2026-10-07
Recruiting
Pfizer
Phase 3
180
Mihama-ku, Matsuyama, Fukuoka, Kasuya-gun, Sapporo, Amagasaki, Mito, Naka
2026-10-02
Not yet open
Eli Lilly and Company
Phase 1
60
Fukuoka, Sumida-ku, Toshima City
2026-10
Not yet open
Study of BK1803 in Healthy Infants
NCT07793513Pertussis, Diphtheria, Tetanus, Poliomyelitis
Tanabe Pharma Corporation
Phase 3
344
Fukui-shi, Fukuoka, Isesaki, Maebashi, Hiroshima, Ishikari-shi, Sapporo, Amagasaki
2026-10
Recruiting
Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder
NCT07738952Neuromyelitis Optica Spectrum Disorder Attack
Kyushu University
Phase 1/2
7
Fukuoka
2026-10
Recruiting
Kyushu University
Phase 1
21
Fukuoka
2026-10
Recruiting
Pfizer
Phase 3
197
Mihama-ku, Matsuyama, Fukuoka, Kasuya-gun, Sapporo, Amagasaki, Mito, Naka
2026-09-29
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe
2026-09-24
Recruiting
GlaxoSmithKline
Phase 3
610
Fukuoka, Fukushima, Hokkaido, Ibaraki, Miyagi, Numakunai, Osaka, Saitama
2026-09-24
Recruiting
4D Molecular Therapeutics
Phase 3
514
Mito, Amagasaki-shi, Fukuoka, Fukushima, Hachioji-shi, Kagoshima, Kita-Gun, Kobe
2026-09-18
Recruiting
Daiichi Sankyo
Phase 1/2
220
Kashiwa, Isehara, Yokohama, Hirakata, Chuo-ku, Koto-ku, Shinagawa-ku, Fukuoka
2026-09-17
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1/2
50
Chiba, Kashiwa, Fukuoka, Hiroshima, Sapporo, Kanazawa, Yokohama, Kyoto
2026-09-15
Recruiting
AstraZeneca
Phase 3
1,330
Chiba, Fukuoka, Hiroshima, Kamakura-shi, Kawagoe-shi, Kisarazu-shi, Kita-gun, Kobe
2026-09-15
Recruiting
Shionogi
Phase 3
2,000
Kasugai-Shi, Chiba, Fukuoka, Nihommatsu, Annaka-Shi, Fujioka-Shi, Koyagimachi, Maebashi
2026-09-14
Recruiting
Incyte Corporation
Phase 3
426
Bunkyō City, Chūō, Fukuoka, Fukushima, Hirakata, Kagoshima, Kashiwa-shi, Kobe
2026-09-08
Recruiting
AstraZeneca
Phase 3
1,072
Fukuoka, Kanazawa, Maebashi, Nagoya, Sapporo, Yokohama
2026-08-31
Recruiting
GlaxoSmithKline
Phase 3
624
Fukuoka, Tokyo
2026-08-27
Recruiting
AstraZeneca
Phase 3
7,000
Aira, Akita, Asahikawa-shi, Chūōku, Fujisawa-shi, Fukuoka, Hachioji-shi, Hamamatsu
2026-08-21
Recruiting
AstraZeneca
Phase 3
1,500
Aira, Chūōku, Fukuoka, Hachioji-shi, Izunokuni-shi, Kumamoto, Nagoya, Nerima-ku
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Chūōku, Fukuoka, Hachioji-shi, Osaka, Shibuya-ku, Takatsuki-shi
2026-08-19
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
Fukuoka, Hiroshima, Sapporo, Akashi, Yokohama, Tokyo, Natori-shi, Niigata
2026-08-19
Recruiting
Stemline Therapeutics, Inc.
Phase 2
70
Chiba, Fukuoka, Hirakata, Hiroshima, Ina, Isehara, Kagoshima, Kōtō City
2026-08-18
Recruiting
GlaxoSmithKline
Phase 2
24
Fukuoka, Hokkaido, Tokyo
2026-08-17
Recruiting
Eli Lilly and Company
Phase 3
1,000
Fukuoka, Hakata-Ku, Hino, Karatsu, Kawasaki, Kitakyushu, Koshigaya, Kōtō City
2026-08-14
Recruiting
Eli Lilly and Company
Phase 2
606
Chūōku, Fukuoka, Iizuka, Osaka, Sendai, Ube
2026-08-07
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
Nagoya, Kanazawa, Chiba, Fukuoka
2026-08-06
Recruiting
GlaxoSmithKline
Phase 3
800
Ehime, Fukuoka, Gifu, Hokkaido, Kanagawa, Osaka, Tokyo, Toyama
2026-07-27
Recruiting
AstraZeneca
Phase 3
915
Fukuoka, Hamamatsu, Hirosaki-shi, Kanazawa, Kashihara-shi, Kawasaki-shi, Kita-gun, Kobe
2026-07-16
Recruiting
National Cancer Center, Japan
Phase 2
136
Chiba, Fukuoka, Gifu, Maebashi, Hiroshima, Kawasaki, Yokohama, Ina
2026-07-15
Recruiting
GlaxoSmithKline
Phase 4
28
Ehime, Fukui, Fukuoka, Gunma, Nagano, Osaka, Saitama, Shiga
2026-07-15
Recruiting
Metagen Therapeutics, Inc.
Phase 1/2
54
Fukuoka, Sapporo, Kurashiki, Hirakata, Hamamatsu, Bunkyō-Ku, Minato-Ku, Mitaka
2026-07-09
Recruiting
Eli Lilly and Company
Phase 3
170
Chiyoda-ku, Fukuoka, Iruma, Moriyama, Niigata, Osaka, Saitama, Sendai
2026-07-08
Recruiting
AstraZeneca
Phase 3
2,000
Chūōku, Fukuoka, Hachioji-shi, Ichikawa-shi, Kamakura-shi, Kishiwada-shi, Kitakyushu, Meguro-ku
2026-07-06
Recruiting
AbbVie
Phase 3
531
Toyoake, Hirosaki, Fukuoka, Sapporo, Kobe, Sagamihara-shi, Sendai, Niigata
2026-07-02
Recruiting
Merck Sharp & Dohme LLC
Phase 2
750
Suita, Arakawa City, Hachiōji, Katsushika-ku, Musashino, Shinjuku, Fukuoka, Nagasaki
2026-06-30
Active, closed
GlaxoSmithKline
Phase 3
102
Aichi, Chiba, Fukui, Fukuoka, Fukushima, Hokkaido, Kanagawa, Kyoto
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Fukuoka, Kyoto, Nishinomiya-shi, Okayama, Sapporo, Shibuya-ku, Shinjuku-ku, Suita-shi
2026-06-26
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 3
784
Aichi, Fukuoka, Hokkaido, Kanagawa, Miyagi, Osaka, Tokyo, Toyama
2026-06-24
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
20
Nagoya, Sapporo, Kobe, Chūō, Fukuoka, Kyoto
2026-06-23
Recruiting
GlaxoSmithKline
Phase 1/2
64
Fukuoka, Hokkaido, Tokyo
2026-06-22
Recruiting
GlaxoSmithKline
Phase 3
450
Fukuoka, Hokkaido, Hyōgo, Kanagawa, Mie, Okinawa, Osaka, Saitama
2026-06-18
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Fukuoka, Hachioji-shi, Hamamatsu, Hiroshima, Kakogawa-shi, Kumagaya-shi, Kumamoto, Matsusaka-shi
2026-06-11
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
20
Fukuoka
2026-06-10
Recruiting
Takeda
Phase 2
92
Fukuoka, Kumamoto, Isahaya-shi, Yodogawa-ku, Osaka-shi, Shinjuku-ku
2026-06-04
Recruiting
GlaxoSmithKline
Phase 3
600
Aichi, Fukuoka, Hokkaido, Hyōgo, Kanagawa, Kyoto, Mie, Numakunai
2026-06-04
Recruiting
Novartis Pharmaceuticals
Phase 1
63
Fukuoka
2026-06-02
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1
120
Fukuoka
2026-06-02
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Chiba, Fukuoka, Gunma, Kamakura-shi, Kyoto, Matsuyama, Okayama, Sapporo
2026-05-31
Recruiting
Pfizer
Phase 3
3,230
Toyota-shi, Fukui-shi, Fukuoka, Kasuga, Sapporo, Hioki, Osaka, Bunkyo
2026-05-29
Recruiting
Takeda
Phase 2
222
Fukuoka, Nagano, Izumisano, Osaka
2026-05-17
Recruiting
Juntendo University
Phase 4
550
Handa, Nagoya, Ōbu, Toyota, Tōon, Fukuoka, Iizuka, Maebashi
2026-05-11
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Nagoya, Fukuoka, Yokohama, Sakai-shi, Kitaadachi-gun, Sunto, Chūōku, Kōtoku
2026-05-06
Recruiting
Novo Nordisk A/S
Phase 3
300
Fukuoka, Hiroshima, Kumamoto, Okinawa, Osaka, Sapporo-shi, Hokkaido, Shizuoka, Tokyo
2026-05-05
Recruiting
AstraZeneca
Phase 3
670
Chiba, Chūōku, Fukuoka, Hamamatsu, Kamakura-shi, Kanazawa, Kashiwa, Kobe
2026-05-04
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Yokohama, Fukuoka, Saitama
2026-04-28
Recruiting
Takeda
Phase 2
42
Tokyo, Fukui, Hiroshima, Kanagawa, Fukuoka, Hyōgo, Yamanashi, Ehime
2026-04-22
Recruiting
Aesculap AG
Observational
178
Fukuoka, Okayama, Kyoto, Osaka-Fu, Osaka
2026-04-10
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
20
Chūōku, Fukuoka, Kanazawa, Nagoya
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Kobe, Shiwa-gun Yahaba-cho, Koto-ku, Toyoma, Fukuoka, Niigata
2026-03-26
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Asahikawa, Bunkyō City, Fujiidera, Fukuoka, Hirosaki, Kagoshima, Kashiwa, Mitaka
2026-03-26
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
2026-03-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
450
Minato, Fukuoka, Tokushima
2026-03-23
Active, closed
AbbVie
Phase 2
14
Nagoya, Yoshida-gun, Fukuoka, Maebashi, Hiroshima, Higashiibaraki-gun, Kyoto, Sakai-shi
2026-03-17
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
2026-03-16
Recruiting
Pfizer
Phase 1/2
132
Shinjuku-ku, Fukuoka, Yamagata
2026-03-11
Recruiting
Takeda
Phase 3
1,182
Minami-ku, Nagoya-shi, Nagoya, Fukuoka, Tsu, Mie, Sasebo-shi, Osaka, Chuo-ku, Meguro-Ku
2026-03-11
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Kashiwa, Koto-Ku, Chiba, Fukuoka, Kanagawa, Osaka, Tokyo, Wakayama
2026-03-09
Recruiting
Incyte Corporation
Phase 3
700
Akashi-shi, Chiba, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kawasaki-shi, Kita-gun
2026-03-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Aichi, Bunkyō City, Chiba, Chūō, Fuchū, Fukuoka, Fukushima, Isehara
2026-03-05
Active, closed
Ipsen
Phase 3
1,300
Chiyoda-ku, Chūōku, Fukuoka, Minatoku, Nerima-ku, Sakaishi, Sapporo, Takatsuki-shi
2026-02-18
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Kashiwa, Matsuyama, Fukuoka, Kashihara-shi, Sakai, Suita, Bunkyo-ku, Koto
2026-02-17
Recruiting
ViiV Healthcare
Phase 2
186
Fukuoka, Kanagawa, Okinawa, Osaka, Tokyo
2026-02-11
Recruiting
Pfizer
Phase 2/3
1,156
Nagoya, Fukuoka, Iizuka-shi, Hiroshima, Kure, Ginowan, Sakai, Fujieda
2026-02-11
Recruiting
GlaxoSmithKline
Phase 1
44
Fukuoka, Hiroshima, Hokkaido
2026-02-10
Recruiting
Pfizer
Phase 1/2
224
Yokohama, Suita, Shinjuku-ku, Fukuoka, Yamagata
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Fukuoka, Kitahiroshima, Kitakyushu, Minatoku, Osaka, Sapporo, Shibuya-ku
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Arakawa City, Chikugo, Chiyoda City, Fukuoka, Fukushima, Ginowan, Hiratsuka, Karatsu
2026-02-09
Recruiting
MSA-01 in Multiple System Atrophy
NCT07446894Multiple System Atrophy (MSA)
Tokyo University
Phase 3
140
Nagoya, Chiba, Fukuoka, Sapporo, Kagoshima, Kyoto, Okayama, Hasuda
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,980
Adachi-ku, Chūōku, Fukuoka, Minato, Mitaka, Suita-shi, Tokyo
2026-02-06
Recruiting
Pancreatic Cancer Screening Using the Enzeavour Assay in Japan
NCT07605819Pancreatic Cancer, Pancreatic Neoplasms
Cosomil, Inc.
Not applicable
10,000
Nagakute, Nagoya, Chiba, Fukuoka, Kasamatsuchō, Hiroshima, Onomichi, Obihiro
2026-02-04
Recruiting
Bristol-Myers Squibb
Observational
150
Chiba, Kashiwa-shi, Sakura, Matsuyama, Chikushino-shi, Fukuoka, Asahikawa, Sapporo
2026-01-29
Recruiting
Tokyo Women's Medical University
Phase 3
950
Akita, Chiba, Fukuoka, Fukushima, Fukuyama, Hamamatsu, Hirakata, Hiroshima
2026-01-28
Recruiting
Takara Bio Inc.
Phase 3
5
Osaka, Fukuoka, Kashiwa
2026-01-05
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Chiba, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima
2025-12-22
Recruiting
Otsuka Pharmaceutical Co., Ltd.
Phase 3
100
Fukuoka
2025-12-22
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Nagoya, Kurume-Shi, Hiroshima, Sapporo, Fukuoka, Akashi, Kobe, Yokohama
2025-12-22
Active, closed
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-12-19
Recruiting
AstraZeneca
Phase 2
320
Aomori, Bunkyō City, Fukuoka, Hamamatsu, Hitachi-Naka, Iizuka-shi, Kawachinagano-shi, Matsuyama
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Yokohama, Chiba, Fukuoka, Kyoto, Tokyo
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Chūōku, Fukuoka, Hirosaki, Kanazawa, Kashiwa, Kawasaki, Kita-ku, Kobe
2025-12-12
Recruiting
Shionogi
Phase 2
192
Kasugai-Shi, Nagoya-Shi Nakamura-Ku, Chikushino-shi, Fukuoka, Fukuoka-Shi Chuo-Ku, Fukuoka-Shi Hakata-Ku, Kitakyushu-Shi Yahatanishi-Ku, Kitakyushu-Shi
2025-12-11
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
Sapporo, Fukuoka
2025-12-05
Recruiting
GlaxoSmithKline
Phase 3
450
Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Kumamoto, Miyagi, Osaka
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
650
Hadano, Kawasaki, Sakai, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Bunkyo-ku, Fukuoka, Okayama
2025-12-02
Recruiting
Pfizer
Phase 3
450
Yokohama, Sakai, Setagaya-ku, Fukuoka
2025-12-02
Recruiting
AbbVie
Phase 2
100
Nagoya, Kashiwa-shi, Fukuoka, Sapporo, Kyoto, Sendai, Okayama, Chuo-Ku
2025-12-01
Recruiting
Pfizer
Phase 1/2
138
Nagoya, Kashiwa, Sakai, Chuo-ku, Fukuoka
2025-12-01
Recruiting
Amgen
Phase 3
750
Nagoya, Matsuyama, Fukuoka, Kobe, Kanazawa, Kita-gun, Sagamihara-shi, Osaka
2025-11-28
Active, closed
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-11-25
Active, closed
AbbVie
Phase 1
142
Ginowan-shi, Fukuoka
2025-11-24
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
14
Nagoya, Fukuoka, Hiroshima, Sapporo, Kyoto, Sendai, Niigata, Ōsaka-sayama
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
900
Osaka, Aichi, Chiba, Ehime, Fukuoka, Gifu, Hiroshima, Hokkaido
2025-11-18
Recruiting
Eli Lilly and Company
Phase 2
252
Fukuoka, Kamakura, Kashiwa, Osaka, Sakura, Sapporo
2025-11-10
Recruiting
National Cancer Center, Japan
Phase 2
27
Fukuoka, Osaka, Tokyo
2025-11-04
Recruiting
AstraZeneca
Phase 3
400
Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kashiwa, Kawasaki-shi, Kyoto, Matsuyama
2025-10-31
Recruiting
GlaxoSmithKline
Phase 2
363
Toyonaka-Shi, Aichi, Fukuoka, Hyōgo, Ibaraki, Ishikawa, Kanagawa, Mie
2025-10-30
Recruiting
Navitor Japan Study
NCT07193888Severe Aortic Stenosis
Abbott Medical Devices
Observational
100
Fukuoka, Kanagawa, Osaka
2025-10-30
Recruiting
Hoffmann-La Roche
Phase 3
600
Aichi, Fukuoka, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Miyagi, Niigata
2025-10-24
Recruiting
Eli Lilly and Company
Phase 3
1,630
Akashi, Chūōku, Fukuoka, Hidaka, Kagoshima, Kashiwa, Kōtoku, Nagoya
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,100
Chūōku, Fukuoka, Karatsu, Kobe, Nagasaki, Nakano, Nishi, Shibuya City
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Amagasaki, Asahikawa, Bunkyō, Bunkyō City, Chikushino-shi, Fukuoka, Gifu, Ginowan
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Chūōku, Fukuoka, Karatsu, Kariya, Kobe, Nagasaki, Nishi, Setagaya City
2025-10-15
Recruiting
AbbVie
Observational
200
Nagakute, Nagoya, Hirosaki, Chiba, Kashiwa-shi, Sakura, Fukuoka, Hiroshima
2025-10-09
Recruiting
Sanofi
Phase 3
980
Asahikawa, Bunkyō City, Chikushino-shi, Chūō, Fukuoka, Kagoshima, Kamakura, Kanazawa
2025-10-08
Recruiting
Kazuya Hosokawa
Phase 4
36
Fukuoka, Kobe, Kyoto, Nagoya, Okayama, Sendai, Tokyo
2025-10-07
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Nagoya, Uwajima-shi, Fukuoka, Kitakyushu, Kurume-shi, Sapporo, Himeji, Kobe
2025-10-02
By invitation
Astria Therapeutics, Inc.
Phase 3
145
Kawagoe, Fukuoka, Kawasaki
2025-10-01
Recruiting
Sanofi
Phase 3
980
Shizuoka, Asahikawa, Bunkyō City, Chikushino-shi, Fukuoka, Hachiōji, Isehara, Isesaki
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Chiba, Chūōku, Fujiidera-shi, Fukui-shi, Fukuoka, Gamagōri, Hamamatsu, Higashiibaraki-gun
2025-10-01
Recruiting
Daiichi Sankyo
Phase 3
710
Akashi-shi, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Kōtoku, Kurume-shi, Niigata
2025-09-30
Recruiting
Genentech, Inc.
Phase 2
224
Kashiwa-shi, Fukuoka, Fukuyama-shi, Kanazawa, Takamatsu, Osaka, Saga, Fujidera-shi
2025-09-29
Recruiting
Daiichi Sankyo
Phase 2/3
630
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kawasaki, Kōtoku, Kumamoto, Kyoto
2025-09-26
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Nagoya-sh, Toyoake Shi, Asahikawa-shi, Suita, Suita-shi, Ōtsu, Chūōku, Fukuoka
2025-09-22
Active, closed
Fabhalta Capsules Specified Drug-use Survey
NCT07156149C3 Glomerulopathy
Novartis Pharmaceuticals
Observational
33
Nagoya, Toyoake, Hirosaki, Chiba, Fukuoka, Kitakyushu, Sapporo, Tsukuba
2025-09-17
Recruiting
Sanofi
Phase 3
942
Kōnan, Nagoya, Toyota, Matsuyama, Fukuoka, Iizuka, Kurume, Kure
2025-09-16
Active, closed
Eli Lilly and Company
Phase 3
800
Fukuoka, Izumo, Kariya, Kawasaki, Minatoku, Miyazaki, Morioka, Saitama
2025-09-15
Recruiting
CSL Behring
Phase 3
200
Fukuoka, Suita, Fuchu-shi
2025-09-15
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Akita, Asahikawa, Fukuoka, Hidaka, Hiroshima, Kobe, Kumamoto, Kurume
2025-09-08
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Bunkyō City, Chikushino-shi, Chūōku, Fukuoka, Hachioji-Shi, Hachiōji, Hakodate-Shi, Hakusan
2025-09-06
Recruiting
CSL Behring
Phase 2
180
Chikushino-shi, Fukuoka, Ibaraki, Iizuka-shi, Kyoto, Mie, Osaka, Shimonoseki-shi
2025-09-03
Recruiting
AbbVie
Phase 2
140
Nagoya, Kashiwa-shi, Fukuoka, Gifu, Yokohama, Sendai, Osaka, Sunto-gun
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Akita, Amagasaki, Bunkyō, Chūōku, Fujisawa, Fukuoka, Gifu, Hachioji-shi
2025-09-02
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Bunkyō City, Fukuoka, Gifu, Hidaka, Kanazawa, Kashiwa, Kobe, Matsuyama
2025-09-02
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Kashiwa, Sunto-gun, Bunkyo-ku, Koto, Fukuoka, Osaka
2025-08-19
Recruiting
Sanofi
Phase 3
90
Nagoya, Tsuchiura, Kanazawa, Fujisawa, Suita, Iruma, Kofu, Fukuoka
2025-08-18
Active, closed
Amgen
Phase 3
350
Matsuyama, Fukuoka, Kurume-shi, Sapporo, Akashi-shi, Niigata, Okayama, Hirakata-shi
2025-08-18
Recruiting
GlaxoSmithKline
Phase 3
420
Fukuoka, Hokkaido, Ishikawa, Kagoshima, Kanagawa, Kochi, Kyoto, Mie
2025-08-11
Active, closed
GlaxoSmithKline
Phase 2
168
Aichi, Fukuoka, Hyōgo, Kumamoto, Okayama, Tokyo
2025-08-06
Recruiting
AstraZeneca
Phase 3
700
Bunkyō City, Fukuoka, Kamakura-shi, Kawagoe-shi, Kawasaki-shi, Kisarazu-shi, Kumamoto, Kyoto
2025-08-06
Not yet open
Encapsulation-oriented vs. Timing-oriented Strategies for Necrotizing Pancreatitis
NCT07106346Walled Off Necrosis, Pancreatitis, Acute Necrotic Collection, Necrotizing Pancreatitis
Tokyo University
Not applicable
224
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kagawa, Kagoshima
2025-08-05
Recruiting
Nippon Medical School
Phase 4
500
Chūō, Fukui, Fukuoka, Fukuyama, Hirakata, Kagoshima, Katsuura, Kawasaki
2025-08-01
Recruiting
Celgene
Phase 3
400
Nagoya, Sapporo, Himeji, Morioka, Chuo-ku, tabashi City, Chūō, Fukuoka
2025-07-28
Recruiting
Pfizer
Phase 3
150
Yokohama, Sakai, Setagaya-ku, Fukuoka
2025-07-24
Recruiting
4D Molecular Therapeutics
Phase 3
480
Nagoya, Hyōgo, Fukushima, Mito, Miyazaki, Ginowan, Chiba, Fukuoka
2025-07-22
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Fukuoka, Chikusa, Nagaizumi-chō, Okayama, Osaka, Sakai, Tokyo, Wakayama
2025-07-17
Recruiting
AstraZeneca
Phase 2
100
Chūōku, Fukuoka, Hidaka-shi, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osaka
2025-07-17
Recruiting
Takeda
Phase 3
347
Kasugai-Shi, Nagoya, Toyoake-shi, Chiba, Fukuoka, Fukushima, Hiroshima, Sapporo
2025-07-15
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Sapporo, Yokohama, Bunkyo-ku, Shinjuku-ku, Chiba, Fukuoka, Okayama, Osaka
2025-07-14
Recruiting
Pfizer
Phase 3
300
Toyoake, Narita, Iizuka, Izumisano, Hachiōji, Shinjuku, Tachikawa, Fukuoka
2025-07-14
Recruiting
Bristol-Myers Squibb
Phase 3
426
Hadano, Kawasaki, Sakai, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Bunkyo-ku, Fukuoka, Okayama
2025-07-10
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Bunkyō City, Fukuoka, Kagawa, Kashihara, Kobe, Kumamoto, Kurume, Matsumoto-shi
2025-07-02
Recruiting
AstraZeneca
Phase 2
987
Chiba, Fukuoka, Fukushima, Ginowan-shi, Hachioji-shi, Hamamatsu, Hiroshima, Izumi-shi
2025-06-27
Recruiting
Hoffmann-La Roche
Phase 3
75
Fukuoka, Nagoya
2025-06-27
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Toyoake-shi, Chiba, Fukuoka, Kitakyushu-shi, Sapporo, Himeji-shi, Takarazuka-shi, Kanazawa
2025-06-25
Recruiting
GlaxoSmithKline
Phase 3
981
Kitakyushu-shi, Chiba, Fukuoka, Fukushima, Gifu, Hokkaido, Hyōgo, Ibaraki
2025-06-20
Recruiting
A First-in-Human Study of PRD001
NCT07034183Healthy Volunteers
PRD Therapeutics, Inc.
Phase 1
86
Fukuoka
2025-06-19
Active, closed
Amgen
Phase 3
279
Nagoya, Fukuoka, Onga-gun, Hashima-gun, Sapporo, Amagasaki-shi, Kobe, Naka
2025-06-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Nagoya, Sapporo, Ginowan, tabashi City, Fukuoka, Kyoto
2025-06-09
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bunkyō City, Fukuoka, Fukushima, Gifu, Kanazawa, Kobe, Kumamoto, Maebashi
2025-06-04
Active, closed
Stoke Therapeutics, Inc
Phase 3
170
Fukuoka, Hokkaido, Kyoto, Nagoya, Niigata, Okayama, Osaka, Shimotsuke
2025-06-04
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Chiba, Kashiwa, Matsuyama, Fukuoka, Maebashi, Sapporo, Akashi-shi, Kobe
2025-05-22
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Aichi-Ken, Cho-ku, Fukuoka, Isehara, Miyagi-Ken, Sapporo
2025-05-20
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Amagasaki-shi, Asahi-shi, Fujisawa-shi, Fukuoka, Fukuoka, Chikushino, Gunma, Maebashi, Hachioji-shi, Hamada-shi
2025-05-20
Recruiting
Eli Lilly and Company
Phase 4
279
Aichi-Ken, Cho-ku, Fukuoka, Isehara, Miyagi-Ken, Sapporo
2025-05-20
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Nagoya, Matsudo, Kawasaki, Yokohama, Habikino, Shinagawa Ku, Fukuoka, Kyoto
2025-05-16
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
Fukuoka, Hyōgo, Ibaraki, Kamakura, Meguro City, Mitaka, Miyagi, Toyota
2025-05-15
Active, closed
Merck Sharp & Dohme LLC
Phase 2
130
Nagoya, Suita, Bunkyo, Mitaka, Fukuoka, Okayama
2025-05-12
Recruiting
Takeda
Phase 2
88
Kohoku-ku, Yokohama-Shi, Kumamoto, Isahaya-shi, Urasoe-Shi, Shinjuku-ku, Sumida-Ku, Fukuoka, Yodogawa-ku, Osaka-shi
2025-05-06
Recruiting
AstraZeneca
Phase 3
1,220
Bunkyō City, Chiba, Fukuoka, Hiroshima, Iizuka-shi, Kashiwa, Kita-gun, Kobe
2025-05-06
Recruiting
Joseph Broderick, MD
Phase 3
350
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Niigata, Osaka
2025-05-06
Recruiting
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
NCT06803823Agitation Associated With Alzheimer's Disease Dementia
Ono Pharmaceutical Co., Ltd.
Phase 2
90
Aichi, Akita, Aomori, Fukui, Fukuoka, Gunma, Hiroshima, Hokkaido
2025-05-01
Active, closed
Hoffmann-La Roche
Observational
44
Fukuoka, Tokyo
2025-04-29
Active, closed
Eli Lilly and Company
Phase 3
905
Chūōku, Ebina, Fukuoka, Hachioji-shi, Kamakura-shi, Kashiwara, Kasugai, Kisarazu
2025-04-25
Recruiting
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
NCT06917690Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
Chiesi Farmaceutici S.p.A.
Phase 3
6
Fukuoka, Kobe, Niigata, Ōta-ku, Sapporo
2025-04-18
Active, closed
EyeBiotech Ltd.
Phase 2/3
1,054
Nagoya, Hirosaki, Sakura, Yoshida-gun, Fukuoka, Kurume, Asahikawa, Amagasaki
2025-04-16
Recruiting
AstraZeneca
Phase 3
830
Akashi, Bunkyō City, Fukuoka, Hamamatsu, Iwakuni-shi, Izumi-shi, Kashihara-shi, Kobe
2025-04-10
Recruiting
Gilead Sciences
Phase 3
695
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kobe
2025-04-04
Active, closed
Philip Morris Products S.A.
Not applicable
290
Fukuoka, Gunma, Hyōgo, Tokyo, Yamagata, Yokohama, Yotsuya
2025-04-02
Recruiting
Eli Lilly and Company
Phase 3
700
Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kobe
2025-03-27
Recruiting
AstraZeneca
Phase 2
540
Fukuoka, Ginowan-shi, Hiroshima, Ishinomaki, Kawaguchi-shi, Kiyose-shi, Kobe, Meguro-ku
2025-03-26
Recruiting
AstraZeneca
Phase 3
990
Akashi-shi, Chikushino-shi, Chiyoda-ku, Fukui-shi, Fukuoka, Gifu, Iruma-Gun, Ishinomaki
2025-03-25
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Fukuoka, Tsu, Kawagoe, Saitama, Hiroshima, Kawasaki, Nagasaki, Saga
2025-03-20
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Chiba, Sapporo, Kobe, Sendai, Suita, Bunkyo Ku, Shinjuku-ku, Fukuoka
2025-03-13
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Nagoya, Kashiwa, Nishinomiya, Kanazawa, Shibuya-ku, Fukuoka, Kumamoto, Okayama
2025-03-12
Active, closed
Takeda
Phase 3
601
Minami-ku, Nagoya-shi, Nagoya, Sapporo, Fukuoka, Ono-shi, Tsu, Mie, Sendai, Sasebo-shi
2025-03-10
Active, closed
Shockwave Medical, Inc.
Not applicable
81
Asahi, Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Miyagi, Nara
2025-03-10
Recruiting
GlaxoSmithKline
Phase 1/2
305
Chiba, Fukuoka, Tokyo
2025-03-04
Recruiting
AstraZeneca
Phase 3
840
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hidaka-shi, Hirakata-shi, Hiroshima, Kasama-shi
2025-03-01
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
538
Konan-shi, Toyoake-shi, Hachinohe-shi, Chiba, Ichikawa-shi, Fukuoka, Kokuraminami-ku, Kitakyushu-shi, Omuta-shi
2025-02-28
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Kashiwa, Sapporo, Kobe, Yokohama, Chiba, Fukuoka, Fukushima, Ishikawa
2025-02-27
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Fukuoka, Kita Gun, Nagoya, Osaka, Ōita, Sasebo, Sendai, tabashi City
2025-02-21
Active, closed
GlaxoSmithKline
Phase 2
307
Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima, Hokkaido, Hyōgo
2025-02-10
Active, closed
NovoCure GmbH
Phase 3
741
Toyoake-shi, Isehara, Fukuoka, Hokkaido, Ishikawa, Kumamoto, Kyoto, Mitaka
2025-02-03
Recruiting
BioNTech SE
Phase 3
621
Ageo, Bunkyō City, Chūōku, Fukuoka, Hidaka, Himeji, Iwakuni, Kobe
2025-02-03
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Fukuoka, Hiroshima, Kanagawa, Osaka, Tokyo
2025-02-01
Recruiting
Incyte Corporation
Phase 3
240
Aichi, Aichi-ken, Fukuoka, Hiroshima, Hyōgo, Isehara Kanagawa, Kumamoto Kumamoto, Maebashi
2025-01-21
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Nagoya, Fukuoka, Asahikawa, Ibaraki, Kagoshima, Sagamihara, Yokohama, Kanagawa
2025-01-08
Active, closed
Daiichi Sankyo
Phase 2
335
Akashi, Chūōku, Fukuoka, Hidaka, Kashiwa, Kōtoku, Nagoya, Osaka
2025-01-06
Active, closed
AbbVie
Phase 3
99
Nagoya, Toyoake, Matsudo-Shi, Fukuoka, Kasuga-shi, Kitakyushu-shi, Maebashi, Sapporo
2024-12-22
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Sapporo, Yokohama, Sendai, Suita, Izumo, Bunkyo-ku, Shinjuku-ku, Fukuoka
2024-12-17
Recruiting
GlaxoSmithKline
Phase 3
520
Shibuya-Ku, Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hyōgo, Ibaraki
2024-12-16
Recruiting
Pfizer
Phase 3
2,330
Kasugai, Narita, Fukuoka, Okawa-shi, Sapporo, Himeji, Koga-shi, Tsuchiura
2024-12-08
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
56
Urayasu, Kobe, Kashihara, Fukuoka, Miyazaki, Tokyo
2024-12-05
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Chūōku, Fuchū, Fukuoka, Kawachi-Nagano, Naha, Okayama, Sapporo, Sasebo
2024-12-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Yotsukaidō, Tsuchiura, Kiyose, Toshimaku, Fukuoka, Kumamoto
2024-12-02
Active, closed
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Observational
94
Fukuoka
2024-11-28
Recruiting
AstraZeneca
Phase 3
1,160
Amagasaki-shi, Bunkyō City, Chūōku, Fukuoka, Hiroshima, Kawagoe-shi, Kawasaki-shi, Kitaadachi-gun
2024-11-27
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
23
Nagoya, Sapporo, Kobe, Osaka, Chuo-ku, Chiba, Fukuoka, Fukushima
2024-11-25
Recruiting
UCB Biopharma SRL
Phase 3
450
Bunkyō City, Chūōku, Fukuoka, Kawagoe, Kawasaki-shi, Kita-gun, Kitakyushu, Kurashiki
2024-11-21
Active, closed
Daiichi Sankyo
Phase 3
700
Akita, Aomori, Bunkyō City, Chiba, Fukuoka, Fukuyama, Gifu, Hamamatsu
2024-11-19
Recruiting
AstraZeneca
Phase 3
1,160
Amagasaki-shi, Bunkyō City, Chūōku, Fukuoka, Hirakata-shi, Hiroshima, Kakogawa-shi, Kanazawa
2024-11-18
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Narita-shi, Fukuoka, Sapporo, Okayama, Osaka, Saitama-shi, Mibu-Machi, Kodaira-shi
2024-11-11
Active, closed
Amgen
Phase 2
409
Fukuoka, Mito, Tsuchiura-shi, Kumamoto, Nagasaki, Kashiwara-shi, Shizuoka, Meguro-ku
2024-11-07
Active, closed
Daiichi Sankyo
Phase 1/2
137
Fukuoka, Kashiwa, Kōtoku, Nagoya, Sagamihara-shi
2024-10-30
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Sapporo, Sendai, Suita, Bunkyo-ku, Fukuoka, Ishikawa, Kyoto
2024-10-29
Active, closed
Eli Lilly and Company
Phase 3
1,400
Bunkyō City, Chūōku, Fujisawa, Fukuoka, Hachiōji, Himeji, Imabari, Kobe
2024-10-24
Active, closed
AstraZeneca
Phase 3
25
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Iwakuni-shi, Kashiwa
2024-10-15
Active, closed
Ipsen
Phase 2
670
Fukuoka, Hiroshima, Hyōgo, Kagoshima, Kyoto, Miyagi, Osaka, Shizuoka
2024-10-10
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1
156
Kamogawa, Yoshida, Kurume, Sapporo, Hirakata, Mibu, Musashino, Fukuoka
2024-10-10
Active, closed
AstraZeneca
Phase 3
768
Bunkyō City, Fukuoka, Hiroshima, Iruma-Gun, Iwakuni-shi, Kobe, Kōtoku, Kumamoto
2024-10-04
Recruiting
GlaxoSmithKline
Observational
300
Fukuoka
2024-10-04
Recruiting
Ferring Pharmaceuticals
Phase 3
454
Nagakute, Nagoya, Narita, Matsuyama, Fukuoka, Hiroshima, Kobe, Hitachi
2024-10-01
Active, closed
Longboard Pharmaceuticals
Phase 3
108
Narita-shi, Fukuoka, Sapporo, Okayama, Osaka, Saitama-shi, Mibu-Machi, Kodaira-shi
2024-09-25
Active, closed
Genmab
Phase 3
699
Nagoya, Kashiwa, Fukuoka, Hiragi, Natori-shi, Sendai, Ōsaka-sayama, Chuo Ku
2024-09-25
Active, closed
ModernaTX, Inc.
Phase 3
37,864
Nagoya, Hiroshima, Sapporo, Fukuoka, Kawasaki-shi, Kyoto, Minoh, Kawagoe-shi
2024-09-24
Active, closed
Hoffmann-La Roche
Phase 3
338
Fukuoka, Miyagi, Osaka, Tokyo, Wakayama
2024-09-23
Active, closed
argenx
Phase 3
141
Chūōku, Fukuoka, Hanamaki-shi, Hiroshima, Kawagoe, Kyoto, Narita, Sapporo
2024-09-18
Active, closed
Hoffmann-La Roche
Phase 3
400
Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima, Kanagawa, Nagasaki
2024-09-17
Recruiting
GlaxoSmithKline
Phase 3
440
Aichi, Fukuoka, Hiroshima, Hokkaido, Kanagawa, Miyagi, Miyazaki, Saitama
2024-09-11
Active, closed
Amgen
Phase 3
315
Nagoya, Funabashi-shi, Fukuoka, Iizuka-shi, Maebashi, Fukuyama, Hiroshima, Asahikawa
2024-09-09
Active, closed
Takeda
Phase 3
2,099
Nagoya, Fukutsu-shi, Obihiro-Shi, Sapporo, Fukuoka, Osaka, Kusatsu-shi, Shimotsuke-shi
2024-09-04
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
Bunkyō City, Fukuoka, Mitaka, Nagoya, Okayama, Shinjuku-Ku, Suita
2024-09-03
Active, closed
Software as a Medical Device for the Treatment of Patients With PTSD
NCT06589505Post-Traumatic Stress Disorder, PTSD
Otsuka Medical Devices Co., Ltd. Japan
Phase 2/3
52
Yamanashi, Akita, Fukuoka, Gunma, Hokkaido, Hyōgo, Ibaraki, Kanagawa
2024-09-01
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Asahikawa-Shi, Chiba, Chuo-Shi, Fukuoka, Isehara, Izumo, Kurashiki-Shi, Kurume
2024-08-30
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Aichi, Amagasaki, Fukuoka, Kahoku, Kanazawa, Kashihara, Kasugai, Kita-ku
2024-08-30
Active, closed
Ferring Pharmaceuticals
Observational
1,526
Chiba, Fukuoka, Kitakyushu, Takasaki, Hiroshima, Bunkyō City, Tokyo, Hokkaido
2024-08-27
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Isesaki-shi, Kagoshima, Kyoto
2024-08-13
Active, closed
Genmab
Phase 3
379
Toyoake, Matsuyama, Fukuoka, Fukushima, Sapporo, Amagasaki, Kagoshima, Isehara
2024-08-13
By invitation
Novo Nordisk A/S
Observational
23
Toshima City, Aomori, Fukuoka, Hokkaido, Kagoshima, Kanagawa, Kitakyusyu-shi, Fukuoka, Okinawa
2024-08-08
Recruiting
AstraZeneca
Phase 3
1,018
Bunkyō City, Chiba, Chuo-shi, Fukuoka, Hirakata-shi, Kobe, Kōtoku, Kumamoto
2024-08-07
Active, closed
TAV-in-SAV in Japanese Patients
NCT06826027Valve-in-valve Procedures
Osaka University
Observational
180
Urayasu, Fukuoka, Kurume, Okayama, Osaka, Suita, Saga, Koshigaya
2024-08-07
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
60
Fukuoka, Kashiwa-shi, Kōtoku, Kumamoto
2024-08-07
Active, closed
Incyte Biosciences Japan GK
Phase 3
21
Aichi, Fukui, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Kumamoto
2024-07-30
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Nagoya, Chiba, Kashiwa, Matsuyama, Fukuoka, Sapporo, Kanazawa, Kagoshima
2024-07-19
Recruiting
Amgen
Phase 3
450
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Akashi-shi, Kawasaki-shi
2024-07-17
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Sayama, Kawagoe, Yaizu, Bunkyo-Ku, Kodaira, Chiba, Fukuoka, Saga
2024-07-12
Active, closed
Amgen
Phase 3
89
Fukuoka, Mito, Kanazawa, Miyazaki, Osaka-Shi Yodogawa-Ku
2024-07-05
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Kashiwa-shi, Matsuyama, Gifu, Ota-Shi, Kure, Sapporo, Fukuoka, Akashi
2024-06-30
Active, closed
AstraZeneca
Phase 3
339
Chūōku, Fukuoka, Kanazawa, Kita-gun, Nagoya, tabashi City, Wakayama, Yokohama
2024-06-29
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Fukuoka, Asahikawa, Kita-gun, Sagamihara, Yokohama, Nagano, Kawachi-Nagano, Osaka
2024-06-28
Active, closed
Genmab
Phase 3
621
Chūōku, Fukuoka, Kashiwa, Miki, Nagoya, Natori, Ōsaka-sayama, Sendai
2024-06-25
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Miyazaki, Aichi, Chiba, Ehime, Fukuoka, Fukuoka-shi, Fukuoka, Himeji-shi, Hyogo, Hokkaido
2024-06-25
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Chiba, Narita-shi, Fukuoka, Koriyama-shi, Hakodate-shi, Hanamaki-shi, Kita-gun, Nagasaki
2024-06-25
Recruiting
AstraZeneca
Phase 3
240
Asahikawa-Shi, Bunkyō City, Chiba, Fukuoka, Hiroshima, Iruma-Gun, Kawachinagano-shi, Kawasaki-shi
2024-06-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Toyoake, Tōon, Fukuoka, Ōta, Kanazawa, Kawasaki, Yokohama, Natori-shi
2024-06-11
Active, closed
GlaxoSmithKline
Phase 3
88
Aichi, Ehime, Fukuoka, Hokkaido, Hyōgo, Kyoto, Mie, Miyagi
2024-06-10
Active, closed
GlaxoSmithKline
Phase 4
302
Fukuoka, Miyagi, Osaka, Tokyo
2024-06-06
Active, closed
Amgen
Phase 3
563
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Sapporo, Akashi-shi, Yokohama
2024-06-05
Active, closed
Amgen
Phase 1/2
94
Nagakute-shi, Fukuoka, Mito, Miyazaki
2024-05-30
Recruiting
Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)
NCT06436092Stable Angina, Non-ST-elevation Acute Coronary Syndrome, Unstable Angina
TCROSS Co., Ltd.
Observational
280
Ichinomiya, Toyoake, Chiba, Matsudo, Urayasu, Matsuyama, Fukuoka, Kitakyushu
2024-05-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Nagoya, Toyoake, Kashiwa, Matsuyam, Fukuoka, Kurume, Ōta, Sapporo
2024-05-24
Recruiting
Daiichi Sankyo
Phase 3
540
Chūōku, Fukuoka, Hirakata-shi, Kashiwa, Kōtoku, Matsuyama, Nakatogari, Okayama
2024-05-21
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
220
Sakura, Yokohama, Mitato, Fukuoka
2024-05-20
Active, closed
AbbVie
Phase 3
421
Anjo, Nagoya, Chiba, Yoshida-gun, Fukuoka, Gifu, Maebashi, Fukuyama
2024-05-19
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
20
Nagoya, Akita, Urayasu-shi, Fukuoka, Kitakyushu-shi, Kurume-shi, Fukushima, Gifu
2024-05-17
Recruiting
Boehringer Ingelheim
Phase 2
175
Akita, Amagasaki-shi, Fukuoka, Fukushima, Hachioji-shi, Kagawa, Kita-gun, Kagoshima, Kashihara
2024-05-15
Active, closed
GlaxoSmithKline
Phase 2
41
Aichi, Fukuoka, Gunma, Hokkaido, Hyōgo, Numakunai, Okayama, Osaka
2024-05-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
473
Nagoya, Kashiwa, Nankoku, Kitaadachi-gun, Chūō, Koto, Fukuoka, Osaka
2024-05-03
Recruiting
AstraZeneca
Phase 3
582
Chūōku, Fukuoka, Kashiwa, Kōtoku, Niigata, Osaka, Sakai, Sapporo
2024-04-29
Recruiting
Eli Lilly and Company
Phase 3
510
Aichi, Chiba, Chūō, Fukui, Fukuoak, Fukuoka, Habikino-shi, Hirakata
2024-04-29
Active, closed
GlaxoSmithKline
Phase 4
1,358
Fukuoka, Gifu, Hiroshima, Hyōgo, Kagawa, Kagoshima, Kanagawa, Kumamoto
2024-04-16
Recruiting
AstraZeneca
Phase 3
3,850
Beppu-shi, Bunkyō City, Fujisawa-shi, Fukui-shi, Fukuoka, Fukutsu-shi, Hakusan-shi, Higashiibaraki-gun
2024-04-12
Recruiting
AstraZeneca
Phase 3
675
Bunkyō City, Fukuoka, Hakodate-shi, Hidaka-shi, Hirakata-shi, Hirosaki-shi, Hiroshima, Kanazawa
2024-04-11
Recruiting
Otsuka Medical Devices Co., Ltd. Japan
Phase 1/2
49
Fukuoka, Sapporo, Kagoshima, Miyazaki, Nagasaki
2024-04-01
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Bunkyō City, Chiba, Fukuoka, Kamakura, Kasugai-shi, Kitakyushu-shi, Kobe, Matsumoto-shi
2024-03-29
Active, closed
Takeda
Phase 2
213
Sakura, Sapporo, Hirakata, Minato, Minato-ku, Mitaka, Fukuoka, Saga
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
Chūōku, Daito-shi, Fujisawa-shi, Fukuoka, Hiroshima, Ina-shi, Kamakura-shi, Kasugai-shi
2024-03-29
Active, closed
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
260
Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kyoto, Nagoya, Osaka, Tochigi
2024-03-27
Recruiting
GlaxoSmithKline
Phase 3
864
Aichi, Aomori, Chiba, Ehime, Fukuoka, Gunma, Hokkaido, Hyōgo
2024-03-21
Active, closed
Kite, A Gilead Company
Phase 2
25
Chiba, Fukuoka, Hokkaido, Kyoto, Miyagi, Okayama, Tokyo
2024-03-18
Recruiting
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
NCT06342414Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Primary Liver Cancer
City of Hope Medical Center
Observational
400
Fukuoka, Kumamoto, Sapporo, Tokushima
2024-03-15
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Maebashi, Sapporo, Hizume, Kawasaki, Yokohama, Ehime, Fukuoka, Gifu
2024-03-13
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Kashiwa, Sapporo, Kobe, Yokohama, Chuo Ku, Fukuoka, Fukushima, Ishikawa
2024-03-12
Active, closed
Eli Lilly and Company
Phase 3
17,300
Asahi, Asahikawa, Chikushino-shi, Chūō, Chūōku, Fukuoka, Hakodate, Hakusan
2024-03-05
Active, closed
AstraZeneca
Phase 3
594
Fukuoka, Kashiwa, Kōtoku, Nagoya, Ogaki-shi, Osaka, Sunto-gun, Tokyo
2024-03-04
Recruiting
Daiichi Sankyo
Phase 2/3
860
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kōtoku, Minatoku, Nagaizumi-cho
2024-02-27
Active, closed
Daiichi Sankyo
Phase 1
210
Chūōku, Fukuoka, Kashiwa, Kōtoku, Nagoya, Osaka, Ōsaka-sayama, Shizuoka
2024-02-22
Recruiting
AstraZeneca
Phase 3
5,250
Chūōku, Fujieda-shi, Fukuoka, Kitakyushu, Kobe, Kure-shi, Kyoto, Minoh
2024-02-21
Active, closed
Novo Nordisk A/S
Phase 2
88
Fukuoka, Hiroshima, Kumamoto-shi, Kumamoto, Nagano, Nagasaki, Okayama
2024-02-20
Active, closed
AbbVie
Observational
1,200
Nagoya, Toyoake, Hirosaki, Chiba, Sakura, Fukuoka, Fukushima, Asahikawa-shi
2024-02-19
Active, closed
Genmab
Phase 3
1,095
Toyoake, Matsuyama, Yoshida-gun, Fukuoka, Fukuyama, Sapporo, Kobe, Hitachi-shi
2024-02-05
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Bunkyō City, Fukuoka, Hamamatsu, Kanazawa, Kyoto, Nagasaki, Narita, Niigata
2024-01-22
Recruiting
Bristol-Myers Squibb
Observational
600
Minato-ku, Fukuoka
2024-01-22
Active, closed
Janssen Research & Development, LLC
Phase 3
774
Fukuoka, Fukutsu, Gifu, Ginowan, Gunma, Hokkaido, Isehara, Kawasaki
2024-01-17
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
226
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Yahatanishi-ku, Kitakyusyu-shi, Ota-shi, Hiroshima, Akashi-shi
2024-01-10
Recruiting
ROSA Knee Intraoperative Planning Flexibility Study
NCT05966519Osteo Arthritis Knee, Rheumatoid Arthritis
Zimmer Biomet
Observational
80
Fukuoka
2024-01-05
By invitation
Sanofi
Phase 3
90
Isehara, Tsu, Ureshino, Fukuoka
2024-01-03
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Nagoya, Chuo-ku, Chūō, Fukuoka
2023-12-29
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Bunkyō City, Chiba, Chūōku, Fukuoka, Kashiwa, Kyoto, Okayama, Osaka
2023-12-29
Active, closed
Sanofi
Phase 3
943
Kōriyama, Asahikawa, Himeji, Sagamihara, Higashi-Matsuyama, Kodaira, Chiba, Fukuoka
2023-12-27
Recruiting
Eli Lilly and Company
Phase 3
1,264
Asahikawa, Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kasama
2023-12-21
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Fukuoka, Gifu, Izumi-shi, Ōta-ku, Sendai
2023-12-20
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Nagoya, Hirosaki-Shi, Fukuoka, Sagamihara, Kumamoto, Sendai, Okayama, Hirakata
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Toyoake, Hirosaki, Kashiwa, Matsuyama, Fukuoka, Kurume, Ōta, Himeji
2023-12-15
Recruiting
AstraZeneca
Phase 3
1,145
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe
2023-12-14
Recruiting
AstraZeneca
Phase 3
625
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu, Hidaka-shi
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Chiba, Fukuoka, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashihara-shi, Kawagoe-shi, Kisarazu-shi
2023-11-21
Recruiting
Amgen
Phase 3
750
Nagoya, Hirosaki-shi, Chiba, Kashiwa-shi, Matsuyama, Toon-shi, Fukuoka, Kitakyushu-shi
2023-11-16
Active, closed
AstraZeneca
Phase 3
1,902
Akashi-shi, Akita, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu
2023-11-14
Active, closed
AstraZeneca
Phase 3
314
Bunkyō City, Fukuoka, Iruma-Gun, Kanazawa, Maebashi, Nagasaki, Nagoya, Sapporo
2023-11-08
Active, closed
AstraZeneca
Phase 3
1,835
Chūōku, Fujisawa-shi, Fukui-shi, Fukuoka, Hashima-gun, Kamakura-shi, Kasuga-shi, Kawaguchi-shi
2023-11-07
Not yet open
WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts
NCT06133023Pancreatic Fluid Collection, Pancreatitis, Pancreatic Pseudocyst
Tokyo University
Not applicable
80
Aichi, Bunkyō-Ku, Tokyo, Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima
2023-11
Active, closed
Sound Wave Innovation CO., LTD.
Phase 3
220
Nagoya, Ōbu, Narita, Fukuoka, Hiroshima, Sapporo, Toride, Kanazawa
2023-10-31
Active, closed
Summit Therapeutics
Phase 3
1,600
Aichi, Fukuoka, Hirosaki, Hiroshima, Hokkaido, Kashihara, Matsumoto, Miyagi
2023-10-26
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Showa-Ku, Toyoake-shi, Chiba, Kamogawa-shi, Yoshida-gun, Chikushino-shi, Fukuoka, Koriyama-shi
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Bunkyō City, Fukuoka, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Okayama
2023-10-24
Active, closed
Celgene
Phase 3
79
Nagoya, Sapporo, Nishinomiya, Kanazawa, Isehara, Shibuya-ku, Chiba, Fukuoka
2023-10-16
Active, closed
Stichting European Myeloma Network
Phase 3
759
Bunkyō City, Fukuoka, Hokkaido, Hyōgo, Kanazawa, Nagoya, Okayama, Osaka
2023-10-10
Active, closed
AstraZeneca
Phase 3
5,511
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Hirakata-shi, Hiroshima, Iruma-Gun
2023-10-05
By invitation
Novo Nordisk A/S
Observational
200
Aichi, Aomori, Asahikawa, Hokkaido, Beppu-shi, Oita-ken, Chiba, Fukuoka, Fukuoka-shi, Fukuoka-ken, Fukuoka-shi, Fukuoka
2023-10-04
Active, closed
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
NCT06547528Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugONO-4685
Ono Pharmaceutical Co., Ltd.
Phase 1
108
Nagoya, Akita, Kashiwa-shi, Fukuoka, Sapporo, Isehara-shi, Kumamoto, Kyoto
2023-10-01
Active, closed
AstraZeneca
Phase 1/2
166
Fukuoka, Shinjuku-ku, Suita-shi
2023-09-29
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Fukuoka, Ota-Shi, Kobe, Tsukuba, Kita-gun, Yokohama, Tokushima, Wakayama
2023-09-22
Recruiting
AstraZeneca
Phase 3
800
Fukuoka, Ginowan-shi, Hidaka-shi, Kagoshima, Kōtoku, Kurume-shi, Maebashi, Matsuyama
2023-09-22
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Kyoto
2023-09-18
Recruiting
Protara Therapeutics
Phase 2
131
Komaki-shi, Nagoya, Funabashi-shi, Sakura-shi, Fukuoka, Amagasaki-shi, Hitachi-shi, Yokohama
2023-09-15
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Chiba, Fukuoka, Koriyama-shi, Naka-gun, Hiroshima, Sapporo, Himeji-Shi, Kobe
2023-09-14
Active, closed
Hoffmann-La Roche
Phase 3
687
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Ishikawa, Kanagawa
2023-09-14
Active, closed
Cytokinetics
Phase 3
500
Fukuoka, Hyōgo, Ibaraki, Kanagawa, Kochi, Kyoto, Mie, Miyagi
2023-08-31
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
200
Fukuoka, Kawasaki, Miyagi, Tokyo
2023-08-30
Recruiting
AstraZeneca
Phase 3
231
Fukuoka, Fukuyama, Funabashi-shi, Nara, Odawara, Ōtsu, Saga, Shimotsuga-gun
2023-08-24
Active, closed
Hoffmann-La Roche
Phase 3
459
Aichi, Aomori, Chiba, Chūō, Ehime, Fukuoka, Hiroshima, Hokkaido
2023-08-08
Recruiting
GlaxoSmithKline
Phase 3
892
Aichi, Chiba, Fukuoka, Hokkaido, Hyōgo, Ibaraki, Kanagawa, Kyoto
2023-08-01
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Nagoya, Kashiwa-shi, Fukuoka, Sendai, Niigata, Sayama, Sunto-gun, Chuo Ku
2023-07-31
Active, closed
Incyte Corporation
Phase 2
247
Chūōku, Fukuoka, Kishiwada, Kitakyushu-shi, Mizunami-shi, Osaka, Sakaide-shi, Sapporo
2023-07-11
Active, closed
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome
NCT05914155Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic
DrugRituximab
Shoichi Maruyama MD PhD
Phase 3
88
Anjo, Kasugai, Kōnan, Nagoya, Toyoake, Urayasu, Fukuoka, Kurume
2023-06-24
Active, closed
AbbVie
Phase 3
1,328
Fukuoka, Nishinomiya-shi, Tsukuba, Kyoto, Sendai, Ginowan-shi, Sakai-shi, Ōtsu
2023-06-21
Active, closed
AbbVie
Observational
1,019
Nagoya, Hirosaki-shi, Chiba, Sakura-shi, Chikushino-shi, Fukuoka, Asahikawa-shi, Sapporo
2023-06-09
Recruiting
Hoffmann-La Roche
Phase 3
200
Chiba, Chuo-ku, Fukuoka-shi, Fukuoka, Kanagawa, Kashiwa-shi, Matsuyama, Numakunai, Saitama
2023-06-01
Recruiting
Eli Lilly and Company
Phase 1/2
880
Fukuoka, Hirakata, Kōtō City, Kyoto
2023-04-17
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Aichi, Bunkyō City, Chiba, Chikushino-shi, Fukuoka, Funabashi-shi, Gifu, Higashiibaraki-gun
2023-04-11
Active, closed
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
NCT05729711Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
AstraZeneca
Observational
416
Aichi, Akita, Aomori, Chiba, Fukui, Fukuoka, Gifu, Gunma
2023-04-04
Recruiting
AstraZeneca
Phase 3
4,300
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Hirakata-shi, Hiroshima, Isehara-shi
2023-03-31
Recruiting
National Cancer Center, Japan
Phase 2
32
Kashiwa, Sapporo, Kyoto, Sendai, Chuo-ku, Fukuoka
2023-03-29
Active, closed
Otsuka Medical Devices Co., Ltd. Japan
Not applicable
24
Urayasu, Fukuoka, Kitakyushu, Kamakura, Osaka City, Osaka
2023-03-10
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Chiba, Chikushino-shi, Fukuoka, Gifu, Hachiōji, Hamamatsu, Hatsukaichi, Hidaka
2023-02-15
Active, closed
Genmab
Phase 3
900
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe, Tsukuba
2023-02-08
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Nagakute, Shibukawa, Sapporo, Okayama, Iruma-gun, Chiba, Fukuoka, Gifu
2023-02-03
Active, closed
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562Diffuse Large B-Cell Lymphoma
Tanabe Pharma Corporation
Phase 1/2
46
Nagoya, Kashiwa-shi, Fukuoka, Iizuka-shi, Fukushima, Gifu, Ota-shi, Sapporo
2023-01-30
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Chūō, Fukuoka, Kyoto, Osaka, Sapporo, Tokyo
2023-01-23
Active, closed
Daiichi Sankyo
Phase 3
1,233
Ehime, Fukoka, Fukuoka, Hokkaido, Hyōgo, Ishikawa, Kanagawa, Kumamoto
2023-01-11
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Fukui, Fukuoka, Gifu, Hiroshima, Kagawa, Kagoshima, Kanagawa, Nagano
2023-01-02
Active, closed
Ferring Pharmaceuticals
Phase 3
25
Nagakute-shi, Nagoya, Narita-shi, Matsuyama, Fukuoka, Hiroshima, Hakodate-shi, Sapporo
2022-12-21
Active, closed
Viatris Innovation GmbH
Phase 3
470
Amagasaki-shi, Bunkyō City, Chiba, Chuo-shi, Chūōku, Fukuoka, Hiroshima, Hitachi-Naka
2022-12-13
Recruiting
AstraZeneca
Phase 3
3,527
Chiba, Fukuoka, Gifu, Ginowan-shi, Hanyu-shi, Hiroshima, Hitachi-shi, Isehara-shi
2022-12-13
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Aichi, Akita, Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima
2022-12-05
Active, closed
Kringle Pharma, Inc.
Phase 3
62
Toyoake, Fukuoka, Kurume, Kamigyō-ku, Sendai, Kurashiki, Chiyoda-ku, Minato-Ku
2022-12-01
By invitation
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Kurume-Shi, Fukuoka, Hamamatsu, Kumamoto, Kurume, Matsumoto, Okayama, Osaka
2022-11-30
Active, closed
AstraZeneca
Phase 3
1,174
Akashi-shi, Chiba, Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kashiwa
2022-11-28
Recruiting
National Cancer Center Hospital East
Phase 3
608
Chiba, Ehime, Fukuoka, Gifu, Hirosaki, Hiroshima, Kawasaki, Kitakyushu
2022-11-21
Active, closed
Regeneron Pharmaceuticals
Phase 3
63
Nagoya, Yufu, Fukuoka
2022-11-21
Recruiting
Pfizer
Phase 3
1,060
Yoshida-gun, Maebashi, Yahaba-cho, Sendai, Nagaizumi-cho, Shibuya-ku, Fukuoka, Okayama
2022-11-10
Active, closed
AstraZeneca
Phase 3
368
Akita, Fukuoka, Himeji, Hiroshima, Isehara-shi, Kawasaki-shi, Maebashi, Minatoku
2022-11-10
Active, closed
Hoffmann-La Roche
Phase 3
68
Fukuoka, Hyōgo, Kagoshima, Kumamoto, Osaka, Tokyo
2022-11-01
Recruiting
Kyushu University
Phase 1
61
Fukuoka
2022-10-26
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Kobe, Kita-gun, Kawasaki-shi
2022-10-24
Active, closed
GlaxoSmithKline
Phase 2
351
Chiba, Fukuoka, Hyōgo, Kanagawa, Osaka, Saitama
2022-10-14
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Bunkyō City, Chiba, Fukuoka, Gifu, Gunma, Hirakata, Hyōgo, Kamakura-shi
2022-10-13
Active, closed
Gilead Sciences
Phase 3
1,021
Chiba, Ehime, Fukuoka, Hyōgo, Ishikawa, Kanagawa, Miyagi, Niigata
2022-10-12
Active, closed
Eli Lilly and Company
Phase 3
15,374
Chūōku, Fukuoka, Izumisano, Kyoto, Minatoku, Onga-gun, Osaka, Uji
2022-10-11
Active, closed
Eli Lilly and Company
Phase 3
8,000
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Fukuyama, Gifu, Hachioji-shi
2022-10-04
Active, closed
Hoffmann-La Roche
Phase 3
122
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Miyagi
2022-09-27
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Abiko, Chikushino-shi, Fukuoka, Fukuoka-ken, Hiroshima, Kagoshima, Kashihara, Kashiwa
2022-09-27
Active, closed
Genmab
Phase 3
549
Nagoya, Toyoake, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe
2022-09-20
Active, closed
Eli Lilly and Company
Phase 2
46
Kobe, Chuo-ku, Fukuoka
2022-09-20
Recruiting
Guideline Oriented Approach To Lipid Lowering In Asia-Pacific
NCT05325034Cardiovascular Diseases, Acute Coronary Syndrome, Atherosclerosis, Hypercholesterolemia
Stephen Nicholls
Not applicable
2,000
Fukuoka, Mitaka, Osaka
2022-09-15
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Bunkyō City, Chūōku, Fujiidera-shi, Fukuoka, Fukushima, Hachinohe, Hachiōji, Hamamatsu
2022-09-13
Active, closed
Hoffmann-La Roche
Phase 3
139
Chiba, Fukuoka, Fukushima, Hyōgo, Kanagawa, Miyagi, Osaka, Tokyo
2022-08-30
Active, closed
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
NCT06696716Pemphigus, Steroid-resistant Pemphigus
DrugTirabrutinib
Ono Pharmaceutical Co., Ltd.
Phase 3
34
Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hokkaido, Kagoshima, Kanagawa
2022-08-15
Active, closed
GlaxoSmithKline
Phase 3
3,038
Fukuoka, Kanagawa, Tokyo
2022-08-10
Active, closed
AstraZeneca
Phase 3
341
Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Hiroshima, Iwakuni-shi, Kanazawa, Kashiwa
2022-08-03
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Asahikawa, Bunkyō City, Chikushino-shi, Fukuoka, Hachiōji, Hamamatsu, Hirosaki, Hitachi
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
Nagoya, Sapporo, Isehara, Sendai, Sakai, Chuo-ku, Koto, Fukuoka
2022-07-21
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
15
Aichi, Fukuoka, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima
2022-07-12
Active, closed
Daiichi Sankyo
Phase 3
586
Akashi, Fukuoka, Hidaka, Hirakata, Iwakuni, Izumi, Kanazawa, Kōtoku
2022-07-08
Recruiting
Toray Industries, Inc
Phase 1/2
49
Nagoya, Fukuoka, Sapporo, Kumamoto, Matsumoto, Niigata, Hidaka, Nagaizumi-chō
2022-07-06
Active, closed
Otsuka Medical Devices Co., Ltd. Japan
Not applicable
154
Hirosaki-shi, Urayasu-shi, Toon-shi, Chikushino-shi, Fukuoka, Kurume-shi, Iwaki, Seki-shi
2022-07-01
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Shinjuku-ku, Fukuoka, Kumamoto, Mitaka, Miyazaki, Sendai, tabashi City, Tsu
2022-06-30
Recruiting
Priothera SAS
Phase 3
366
Anjo-shi, Nagoya, Kanazawa, Osaka, Shimotsuke-shi, Fukuoka, Hiroshima, Kobe
2022-06-16
By invitation
Biogen
Phase 3
864
Nagoya, Toyoake-shi, Chiba, Fukuoka, Kitakyushu-shi, Hiroshima, Sapporo, Himeji-shi
2022-06-10
Recruiting
Kyushu University
Phase 1/2
176
Fukuoka
2022-06-08
Recruiting
AstraZeneca
Observational
300
Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima
2022-06-02
Recruiting
Innovacell GmbH
Phase 3
290
Sapporo, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kumamoto, Kyoto
2022-05-11
Active, closed
Sanofi
Phase 3
104
Sapporo, Kagoshima, Kawasaki, Sendai, Fukuoka, Tokyo
2022-05-03
Active, closed
Hoffmann-La Roche
Phase 3
208
Fukuoka, Hokkaido, Miyagi, Osaka, Tokyo, Yamagata
2022-04-25
By invitation
AstraZeneca
Phase 3
214
Bunkyō City, Fukuoka, Kanazawa, Kōtoku, Nagoya, Okayama, Saga, Sunto-gun
2022-04-19
Active, closed
ARCAGY/ GINECO GROUP
Phase 3
260
Fukuoka, Fukushima, Kōtoku, Saitama
2022-04-15
Active, closed
Janssen Research & Development, LLC
Phase 1/2
235
Fukuoka, Kofu, Osaka, Toyama
2022-04-11
Active, closed
AstraZeneca
Phase 3
760
Chūōku, Fukuoka, Hiroshima, Kashihara-shi, Kashiwa, Kumamoto, Mitaka-shi, Morioka
2022-03-28
Recruiting
AbbVie
Phase 3
768
Nagoya, Hirosaki-shi, Kashiwa-shi, Fukuoka, Kitakyushu-shi, Kurume-shi, Ota-shi, Fukuyama
2022-03-25
Active, closed
Sanofi
Phase 3
122
Fukuoka, Tokyo
2022-03-11
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Kamogawa, Kashiwa-Shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Tsukuba, Kanazawa
2022-03-07
Active, closed
Daiichi Sankyo
Phase 3
740
Aomori, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Kanazawa, Yokohama, Kumamoto
2022-03-04
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Kashiwa-shi, Yoshida-gun, Fukushima, Isehara-shi, Nagasaki, Bunkyo-ku, Bunkyō City, Fukuoka
2022-02-28
Active, closed
AstraZeneca
Phase 3
390
Chiba, Fukuoka, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata, Osaka
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Bunkyō City, Chiba, Fukuoka, Hidaka-shi, Hirosaki-shi, Kashihara-shi, Kōtoku, Kumamoto
2022-02-18
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Chiba, Fukuoka, Gunma, Hiroshima, Hyōgo, Ishikawa, Kanagawa, Niigata
2022-02-07
By invitation
UCB Biopharma SRL
Phase 3
300
Fukuoka, Hachioji-shi, Hiroshima, Hōfu, Itami, Kodaira, Koshi-shi, Kyoto
2022-02-03
Active, closed
Novo Nordisk A/S
Observational
200
Amagasaki-shi, Hyogo, Chuo-shi, Yamanashi-ken, Fukuoka, Fukuoka-shi, Fukuoka-ken, Fukuoka-shi, Fukuoka, Gifu, Goshogawara-shi, Aomori-ken, Gunma
2022-02-03
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Bunkyō City, Chūōku, Fukui-ken, Fukuoka, Fukuyama, Gamagōri, Gunma, Hachinohe
2022-01-19
Active, closed
Bristol-Myers Squibb
Phase 2
19
Nagoya, Toyoake, Aomori, Kamogawa, Kashiwa-shi, Matsuyama, Yoshida Gun, Fukuoka
2022-01-17
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Sapporo, Isehara, Tsu, Hirakata, Bunkyo, Minato, Chūō, Fukuoka
2022-01-14
Active, closed
AbbVie
Phase 2
210
Nagoya, Fukuoka, Kyoto, Nakagami-gun, Osakasayama-shi
2021-12-28
Active, closed
AstraZeneca
Observational
1,620
Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima
2021-12-21
By invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases
DrugsKITE-197·SPRX002·KITE-753·Tecartus
Kite, A Gilead Company
Observational
1,500
Fukuoka, Kyoto, Okayama, Sapporo Hokkaido, Sendai, Tokyo
2021-12-15
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Nagoya, Chiba, Ichihara, Fukuoka, Sapporo, Kobe, Nishinomiya, Isehara
2021-12-13
Recruiting
UCB Biopharma SRL
Phase 3
350
Fukuoka, Hachioji-shi, Hamamatsu, Hiroshima, Hōfu, Itami, Kodaira, Koshi-shi
2021-12-07
Active, closed
Joseph Broderick, MD
Phase 3
860
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Morioka, Niigata
2021-12-03
Active, closed
Amgen
Phase 3
303
Nagoya, Akita, Kamogawa-shi, Yoshida-gun, Fukuoka, Kurume-shi, Fukushima, Maebashi
2021-11-02
Active, closed
AstraZeneca
Phase 3
454
Chūōku, Fukuoka, Kashiwa, Matsuyama, Niigata, Okayama, Osaka, Sakai
2021-10-28
Active, closed
AstraZeneca
Phase 3
732
Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun
2021-10-18
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Fukuoka, Gifu, Higashiibaraki-gun, Isehara, Kamakura-shi, Kashiwa, Koshigaya, Kumamoto
2021-10-14
Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872Aortic Stenosis, Calcific, Aortic Valve Stenosis
Edwards Lifesciences
Not applicable
2,250
Fukuoka, Sendai, Fuchū, Shinjuku
2021-10-12
Active, closed
Pfizer
Phase 3
77
Yufu, Chuo-ku, Koto, Fukuoka
2021-09-29
Active, closed
Nuvation Bio Inc.
Phase 2
217
Fukuoka, Kashiwa, Miyagi, Nagoya, Osaka, Shizuoka, Tokyo
2021-09-01
Active, closed
Pfizer
Phase 3
38,861
Fukuoka, Itoshima, Amagasaki, Yokohama, Osaka, Kawaguchi, Chuo-ku, Hachioji-shi
2021-08-31
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Bunkyō City, Fukuoka, Hyôgo, Kanazawa, Kyoto, Nagoya, Okayama, Sapporo
2021-08-19
Active, closed
HUYABIO International, LLC.
Phase 3
450
Fukuoka, Matsumoto, Niigata, Okayama, Chuo Ku, Osaka, Nagaizumi-cho, Kōtoku
2021-08-12
Active, closed
AstraZeneca
Phase 3
712
Bunkyō City, Fukuoka, Hamamatsu, Ichikawa-shi, Kanazawa, Kashihara-shi, Kawasaki-shi, Kita-gun
2021-08-05
Active, closed
GlaxoSmithKline
Phase 3
24
Aomori, Fukuoka, Himeji, Kamakura, Kitakyushu, Kochi, Matsuyama, Nagoya
2021-07-28
Active, closed
Biogen
Phase 3
562
Nagoya, Toyoake-shi, Chiba, Narashino-shi, Fukuoka, Kitakyushu-shi, Hiroshima, Sapporo
2021-07-16
Recruiting
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
European Foundation for Study of Chronic Liver Failure
Observational
3,000
Fukuoka, Hiroshima, Kyoto, Nagasaki, Tokyo
2021-07-08
Active, closed
GlaxoSmithKline
Phase 3
40
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Kagoshima, Kanagawa
2021-06-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Nishinomiya, Kawasaki, Sagamihara, Suita, Hidaka, Shinjuku-ku, Chiba, Fukuoka
2021-06-18
Active, closed
Daiichi Sankyo
Phase 1
246
Matsuyama, Fukuoka, Sapporo, Yokohama, Okayama, Chuo Ku, Iwakuni-shi, Ōsaka-sayama
2021-06-11
Active, closed
Daiichi Sankyo
Phase 2
155
Nagoya, Kashiwa, Sapporo, Chuo Ku, Fukuoka, Kagoshima, Kyoto, Nagasaki
2021-06-03
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Fukuoka, Fukushima, Kanazawa, Kashiwa, Kobe, Maebashi, Nagoya, Sapporo
2021-05-19
Active, closed
Pfizer
Phase 3
599
Nagoya, Hirosaki, Chiba, Kashiwa, Matsuyama, Fukuoka, Kure, Sapporo
2021-05-12
Active, closed
Incyte Corporation
Phase 3
899
Fukuoka, Gifu, Ibaraki, Isehara, Kagoshima, Nagoya, Narita-shi, Okayama
2021-05-11
Recruiting
Ipsen
Phase 1/2
240
Fukuoka, Shizuoka, Tokushima, Tokyo
2021-04-29
Active, closed
Hoffmann-La Roche
Phase 3
557
Aichi, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Osaka, Tochigi
2021-04-26
Active, closed
Incyte Corporation
Phase 3
654
Fukuoka, Fukuyama-shi, Gifu, Kagoshima, Kashiwa-shi, Kitakyushu-shi, Kobe, Nagoya
2021-04-15
Active, closed
Takeda
Phase 3
77
Fukuoka, Nishinomiya, Bunkyo City
2021-04-14
Active, closed
Hoffmann-La Roche
Phase 3
342
Aichi, Chiba, Fukuoka, Hiroshima, Kanagawa, Osaka, Tokyo
2021-03-12
Active, closed
Institut de Recherches Internationales Servier
Phase 1
28
Fukuoka, Sapporo
2021-03-10
Active, closed
AbbVie
Phase 1
81
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Chuo-ku
2021-02-23
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
DrugRuxolitinib
Incyte Corporation
Phase 1
140
Aichi, Chiba, Chūō, Fukuoka, Kumamoto
2021-02-23
Active, closed
GlaxoSmithKline
Phase 3
1,720
Fukuoka, Kumamoto, Tokyo
2021-02-15
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Chiba, Fukuoka, Gifu, Hokkaido, Kobe, Koshigaya, Kumamoto, Kurashiki
2021-02-01
Active, closed
Genmab
Phase 3
483
Fukuoka, Fukushima, Fukuyama, Hokkaido, Kashiwa, Kyoto, Matsuyama, Mie
2021-01-13
Active, closed
Daiichi Sankyo
Phase 1
179
Chuo Ku, Kashiwa-shi, Fukuoka, Kōtoku, Matsuyama, Nakatogari, Saitama
2020-12-22
Active, closed
Daiichi Sankyo
Phase 3
605
Akashi, Chūōku, Fukuoka, Hidaka, Hirakata, Kanazawa, Kashiwa, Kōtoku
2020-12-21
Active, closed
Incyte Biosciences Japan GK
Phase 1/2
72
Aichi, Chiba, Fukui, Fukuoka, Hyōgo, Kanagawa, Kōtoku, Kumamoto-ken
2020-12-15
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Fukuoka, Kanazawa, Kashihara, Kawasaki, Niigata, Okayama, Osaka, Saitama
2020-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Nagoya, Kobe, Takarazuka, Yokohama, Hirakata, Takatsuki, Nakatogari, Fukuoka
2020-12-08
Active, closed
Daiichi Sankyo
Phase 3
1,600
Akashi, Chūōku, Fukuoka, Hiroshima, Isehara, Kagoshima, Kashiwa, Kōtoku
2020-12-04
Active, closed
Amgen
Phase 3
135
Fukuoka, Hokkaido, Hyōgo, Ishikawa, Kyoto, Niigata, Osaka, Tokyo
2020-12-04
Active, closed
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248Open-angle Glaucoma, Ocular Hypertension
AbbVie
Phase 1/2
100
Sagamihara-shi, Wako, Izumo-shi, Bunkyo-ku, Tama-shi, Chuo-shi, Fukuoka
2020-11-16
Active, closed
AbbVie
Phase 1
21
Fukuoka, Sapporo, Osaka, Chuo-shi
2020-11-11
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Chiba, Fukuoka, Hokkaido, Hyōgo, Miyagi, Moriguchi, Morioka, Saitama
2020-10-15
Active, closed
Bristol-Myers Squibb
Phase 1/2
31
Suwa, Bunkyo-ku, Chūō, Aomori, Bunkyō City, Fukuoka, Hitachi, Ibaraki, Isehara City, Kanagawa
2020-10-12
Active, closed
Hoffmann-La Roche
Phase 3
992
Aichi, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima
2020-10-09
Active, closed
Acerta Pharma BV
Phase 3
611
Chiba, Chūōku, Fukuoka, Kahoku-gun, Kashiwa, Kobe, Kōtoku, Kumamoto
2020-10-08
Active, closed
AstraZeneca
Phase 3
370
Chūōku, Fukuoka, Hiroshima, Isehara-shi, Kashiwa, Kobe, Kōtoku, Okayama
2020-10-02
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Bunkyō City, Chūōku, Fukuoka, Himeji, Hirakata, Kanazawa, Kashiwa, Kurume
2020-09-30
Active, closed
argenx
Phase 2
229
Bunkyō City, Chiba, Fuchū, Fukuoka, Ginowan, Hakodate, Hiroshima, Kawagoe
2020-09-18
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
70
Chiba, Kashiwa, Matsuyama, Fukuoka, Kurume, Hiroshima, Sapporo, Akashi
2020-09-10
Active, closed
AbbVie
Phase 3
531
Nagoya, Yoshida-gun, Fukuoka, Fukushima, Fukuyama, Sapporo, Kobe, Higashiibaraki-gun
2020-09-10
Active, closed
AbbVie
Phase 3
330
Nagoya, Toyoake, Aomori, Chiba, Kashiwa-shi, Toon-shi, Fukuoka, Fukushima
2020-08-31
Active, closed
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04542824Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
DrugsRituximab and lenalidomide·Gemcitabine and oxaliplatin·Epcoritamab·Lenvatinib
Genmab
Phase 1/2
78
Sendai, Aichi, Chiba, Ehime, Fukuoka, Fukushima, Kagoshima, Kyoto
2020-08-20
Active, closed
AstraZeneca
Phase 3
866
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Gifu, Hidaka-shi, Hiroshima
2020-07-24
Active, closed
Eisai Inc.
Phase 3
1,400
Obu-shi, Fukuoka, Kobe, Kamakura-shi, Kyoto, Sendai, Osaka, Suita-shi
2020-07-14
Active, closed
Celgene
Phase 2
276
Sapporo, Chuo-ku, Minato-ku, Fukuoka
2020-07-14
Active, closed
AstraZeneca
Phase 3
1,012
Bunkyō City, Chiba, Chūōku, Fukuoka, Hamamatsu, Hirakata-shi, Hirosaki-shi, Isehara-shi
2020-07-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Kurume, Kobe, Yokohama, Hirakata, Takatsuki, Fukuoka, Niigata, Osaka
2020-07-06
Active, closed
Actelion
Phase 3
935
Bunkyō City, Fukuoka, Hiroshima, Kagoshima, Kanagawa, Kanazawa, Kobe, Kurume
2020-06-30
Active, closed
Eli Lilly and Company
Phase 3
996
Hirosaki, Kashiwa, Kitakyusyu-shi, Chikushino-shi, Fukuoka, Kiryū, Chuo-ku, Sapporo-shi, Sapporo
2020-06-22
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Fukuoka, Kanazawa, Kyoto, Nagoya, Okayama, Sapporo, Sendai, Shibuya City
2020-06-12
Active, closed
GlaxoSmithKline
Phase 3
494
Aichi, Aomori, Ehime, Fukuoka, Gifu, Gunma, Hyōgo, Kanagawa
2020-05-07
Active, closed
AstraZeneca
Phase 3
818
Chiba, Fukuoka, Fukushima, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku
2020-04-16
Active, closed
Janssen Pharmaceutical K.K.
Phase 2
31
Chūōku, Fukuoka, Hirakata, Matsuyama, Nagoya, Niigata, Sapporo
2020-04-07
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Bunkyō City, Chiba, Fukuoka, Hirosaki, Kawasaki-shi, Kōtoku, Kyoto, Niigata
2020-03-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
6,033
Hachiōji, Fukuoka, Kumamoto, Osaka, Tokyo
2020-02-27
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Nagoya, Kashiwa, Sapporo, Kobe, Yokohama, Suita, Koto, Fukuoka
2020-02-11
Recruiting
Eli Lilly and Company
Phase 2
105
Chūōku, Fukuoka, Kobe
2020-01-22
Active, closed
Pfizer
Phase 3
1,068
Matsuyama, Tōon, Fukuoka, Ōta, Sapporo, Yokohama, Osaka, Sakai
2019-12-30
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
240
Aichi, Aomori, Chiba, Fukuoka, Hokkaido, Kamakura, Miyazaki, Okayama
2019-12-16
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
Bunkyō City, Fukuoka, Kashihara, Kita-gun, Kumamoto, Kurume, Matsumoto, Nankoku
2019-11-26
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Kobe, Isehara-Shi, Kyoto
2019-11-13
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Nagoya, Kashiwa, Hiroshima, Matsuyama, Fukuoka, Sapporo, Nishinomiya, Tsukuba
2019-10-02
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Bunkyō City, Chiba, Chikushino-shi, Ehime, Fujiidera-shi, Fukuoka, Fukuoka-ken, Fukushima
2019-09-26
Active, closed
Pfizer
Phase 3
896
Nagoya, Toyohashi, Kashiwa-shi, Nagareyama-shi, Sakura, Fukuoka, Kasuga, Kasuga-shi
2019-09-05
Active, closed
JCR Pharmaceuticals Co., Ltd.
Phase 2/3
27
Fukui, Fukuoka, Gifu, Hiroshima, Hokkaido, Kanagawa, Kumamoto, Okayama
2019-09-01
Active, closed
Sanofi
Observational
1,860
Sagamihara, Yokohama, Tsu, Habikino, Fuchū, Fukuoka, Fukuyama-shi, Hiroshima
2019-08-15
Rows per page Showing 1–500 of 557
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-japan/city/fukuoka

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,516 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 557 of those studies with a site in Fukuoka.

How many clinical trials are recruiting in Fukuoka?

248 of the 557 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 9 have not yet opened recruitment, 290 are active but closed to new participants, and 10 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fukuoka), 557 studies
PhaseStudiesRecruitingShare
Phase 336014964.6%
Phase 2794014.2%
Phase 1/235236.3%
Observational29135.2%
Phase 12173.8%
Phase 2/31372.3%
Not applicable1031.8%
Phase 41061.8%

Most active sponsors

Lead sponsors with the most studies (Fukuoka)
Lead sponsorStudiesRecruiting
AstraZeneca8738
Eli Lilly and Company3322
GlaxoSmithKline3319
Janssen Research & Development, LLC257
AbbVie235
Hoffmann-La Roche226
Novartis Pharmaceuticals209
Merck Sharp & Dohme LLC187
Daiichi Sankyo175
Pfizer1712
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.